Channel Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Cash & Equivalents	0.51	0.1	0.06	-	-
Cash & Short-Term Investments	0.51	0.1	0.06	-	-
Cash Growth	432.67%	75.02%	-	-	-
Prepaid Expenses	0.07	-	-	-	-
Other Current Assets	0.79	-	-	-	0.07
Total Current Assets	1.37	0.1	0.06	-	0.07
Total Assets	1.37	0.1	0.06	-	0.07
Accounts Payable	1.9	4.62	2.99	2.58	3.41
Accrued Expenses	-	0.65	0.22	-	-
Short-Term Debt	2.19	1.27	0.54	-	0.24
Other Current Liabilities	-	0.01	0.01	-	-
Total Current Liabilities	4.08	6.54	3.76	2.58	3.65
Long-Term Debt	-	-	-	1.1	-
Total Liabilities	4.08	6.54	3.76	3.68	3.65
Common Stock	0	0	0	-	-3.58
Additional Paid-In Capital	18.76	7.07	2.43	-	-
Retained Earnings	-21.47	-13.52	-6.14	-3.68	-
Total Common Equity	-2.71	-6.44	-3.71	-3.68	-3.58
Shareholders' Equity	-2.71	-6.44	-3.71	-3.68	-3.58
Total Liabilities & Equity	1.37	0.1	0.06	-	0.07
Total Debt	2.19	1.27	0.54	1.1	0.24
Net Cash (Debt)	-1.67	-1.17	-0.49	-1.1	-0.24
Net Cash Per Share	-0.30	-0.92	-1.11	-	-
Filing Date Shares Outstanding	6.1	5.88	1.11	-	-
Total Common Shares Outstanding	6.1	3.91	1.11	-	-
Working Capital	-2.71	-6.44	-3.71	-2.58	-3.58
Book Value Per Share	-0.44	-1.65	-3.34	-	-
Tangible Book Value	-2.71	-6.44	-3.71	-3.68	-3.58
Tangible Book Value Per Share	-0.44	-1.65	-3.34	-	-

Updated Nov 13, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q